recombinant human papillomavirus nonavalent vaccine

{
  "id": "MLC-T-ONC-007257",
  "term": "recombinant human papillomavirus nonavalent vaccine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A vaccine that is FDA-approved for use in females and males aged 9 to 45 years to protect against infection with nine types of human papillomavirus (HPV). Recombinant human papillomavirus nonavalent vaccine protects against low-risk HPV types 6 and 11, which cause most genital warts, and against high-risk HPV types 16, 18, 31, 33, 45, 52, and 58, which cause most precancerous lesions and cancers of the cervix, vagina, vulva, anus, and head and neck, including the oropharynx. Recombinant human papillomavirus nonavalent vaccine may also prevent HPV-related cancer of the penis. Also called Gardasil 9.",
    "A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers."
  ],
  "synonyms": [
    "Gardasil 9",
    "nonavalent human papillomavirus recombinant vaccine",
    "nonavalent HPV recombinant vaccine",
    "recombinant HPV nonavalent vaccine",
    "nonavalent HPV VLP vaccine",
    "recombinant human papillomavirus 9-valent vaccine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/recombinant-human-papillomavirus-nonavalent-vaccine/"
}